Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer

Cancer

Volumn 115, Issue 7, 2009, Pages 1412-1423

  Chu, Edward ^a   Schulman, Kathy L ^b   Zelt, Susan ^c   Song, Xue ^b  

^a YALE CANCER CENTER   (United States)

^b Thomson Healthcare   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

5 fluorouracil; Capecitabine; Colorectal cancer; Combined 5 fluorouracil; Complications; Leucovorin, and oxaliplatin; Oxaliplatin, combined capecitabine and oxaliplatin; Pharmacoeconomics

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COUGHING; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FEMALE; FEVER; GASTRITIS; HEADACHE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INFECTION; INSOMNIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NIGHT SWEAT; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL MODEL; VOMITING; WEIGHT REDUCTION;

AGED; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEES, PHARMACEUTICAL; FEMALE; FLUOROURACIL; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 63449087000     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24131     Document Type: Article

References (16)

1. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-1214.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizu- mab plus irinotecan, fluorouracil, and leucovorin for meta- static colorectal cancer. N Engl J Med. 2004;350:2335- 2342.
3. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696-2704.
4. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecita- bine compared with intravenous fluorouracil plus leucovo- rin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097-4106.
5. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic color- ectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282-2292.
6. Scheithauer W, McKendrick J, Begbie S, et al. Oral capeci- tabine as an alternative to intravenous 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol. 2003;14:1735-1743.
7. Cassidy J, Twelves C, Van CE, et al. First-line oral capeci- tabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leu- covorin. Ann Oncol. 2002;13:566-575.
8. Diaz-Rubio E, Tabernero J, Gomez-Espana A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. JClin Oncol. 2007;25:4224-4230.
9. Porschen R, Arkenau HT, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007;25:4217-4223.
10. Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capeci- tabine and 5-fluorouracil/ leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006;17:239-245.
11. Jansman FG, Postma MJ, Brouwers JR. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics. 2007;25:537-562.
12. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs. intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer. 2006;94:1122-1129.
13. Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer. 2006;95:27-34.
14. Mayer RJ. Should Capecitabine replace infusional fluorour- acil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol. 2007;25:4165-4167.
15. Garrison L, Best J, Cassidy J, et al. Cost comparison of XELOX vs. FOLFOX-4 ± bevacizumab in metastatic colorectal cancer. Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, Illinois. Poster 4074.
16. Perrocheau G, Bennouna J, Ducreux M, et al. Cost-minimization analysis of a phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting [abstract]. J Clin Oncol. 2007;25:184s. Abstract 4083.